Nanobiotix Announces Completion of $100 Million Global Equity Offering
Nanobiotix S.A. successfully raised $100 million through a global equity offering, with shares priced at €33.60 each.
Stocks · News reference
Nanobiotix Announces Final Data from Phase 1 Study of JNJ-1900 in Cutaneous Melanoma
Nanobiotix reported updated clinical results from its ongoing Phase 1 Study 1100, evaluating JNJ-1900 (NBTXR3) in patients with anti-PD-1-resistant advanced primary cutaneous melanoma.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care
The HNSCC market is projected to grow from $850 million in 2025 to $2.56 billion by 2036 (10.5% CAGR), driven by HPV-targeted vaccines, checkpoint inhibitors, and biomarker-led patient selection. The US will remain the largest market at $2.082 billion. Key therapies include KEYTRUDA and OPDIVO, with emerging candidates like petosemtamab and amivantamab showing promise in clinical development.
Nanobiotix H1 EPS $(0.82) Down From $(0.12) YoY, Sales $6.533M Down From $30.202M YoY
Nanobiotix (NASDAQ:NBTX) reported quarterly losses of $(0.82) per share. This is a 583.33 percent decrease over losses of $(0.12) per share from the same period last year. The company reported $6.533 million in sales